These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Cancer stem cells: are we missing the target? Jones RJ; Matsui WH; Smith BD J Natl Cancer Inst; 2004 Apr; 96(8):583-5. PubMed ID: 15100335 [No Abstract] [Full Text] [Related]
43. Intrinsic versus acquired drug resistance. Mackillop WJ Cancer Treat Rep; 1986 Jun; 70(6):817-8. PubMed ID: 3731144 [No Abstract] [Full Text] [Related]
44. Therapy-induced enrichment of cancer stem-like cells in solid human tumors: Where do we stand? Martins-Neves SR; Cleton-Jansen AM; Gomes CMF Pharmacol Res; 2018 Nov; 137():193-204. PubMed ID: 30316903 [TBL] [Abstract][Full Text] [Related]
46. In the forefront of basic and translational cancer research - 7th AACR-JCA Joint International Conference. Lazo JS IDrugs; 2007 Apr; 10(4):224-6. PubMed ID: 17390238 [No Abstract] [Full Text] [Related]
48. [Progress in the study of targeted drug delivery systems for cancer stem cells]. Qiao MX; Zhang XJ; Shuang BA; Hu HY; Zhao XL; Chen DW Yao Xue Xue Bao; 2013 Apr; 48(4):477-83. PubMed ID: 23833932 [TBL] [Abstract][Full Text] [Related]
49. [Cancer stem cells as the therapeutic target of tomorrow]. Hatina J Wien Med Wochenschr; 2017 Feb; 167(1-2):25-30. PubMed ID: 26943922 [TBL] [Abstract][Full Text] [Related]
50. The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer. Suresh R; Ali S; Ahmad A; Philip PA; Sarkar FH Adv Exp Med Biol; 2016; 890():57-74. PubMed ID: 26703799 [TBL] [Abstract][Full Text] [Related]
51. Pure multiplicative stochastic resonance of a theoretical anti-tumor model with seasonal modulability. Zhong WR; Shao YZ; He ZH Phys Rev E Stat Nonlin Soft Matter Phys; 2006 Jun; 73(6 Pt 1):060902. PubMed ID: 16906802 [TBL] [Abstract][Full Text] [Related]
52. High-throughput screening finds potential killer of cancer stem cells. Rowan K J Natl Cancer Inst; 2009 Nov; 101(21):1438-9. PubMed ID: 19828869 [No Abstract] [Full Text] [Related]
53. The Wnt signaling pathway in cancer. Duchartre Y; Kim YM; Kahn M Crit Rev Oncol Hematol; 2016 Mar; 99():141-9. PubMed ID: 26775730 [TBL] [Abstract][Full Text] [Related]
54. Molecular Pathways: Targeting Cancer Stem Cells Awakened by Chemotherapy to Abrogate Tumor Repopulation. Chan KS Clin Cancer Res; 2016 Feb; 22(4):802-6. PubMed ID: 26671994 [TBL] [Abstract][Full Text] [Related]
55. Circadian cancer pharmacodynamics. Hrushesky WJ Ann Ist Super Sanita; 1993; 29(4):705-10. PubMed ID: 7985931 [TBL] [Abstract][Full Text] [Related]
57. Epigenetic regulation and therapeutic approaches in cancer. Recillas-Targa F Curr Top Med Chem; 2008; 8(15):1367-78. PubMed ID: 18991724 [TBL] [Abstract][Full Text] [Related]
58. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Goldie JH; Coldman AJ Cancer Treat Rep; 1979; 63(11-12):1727-33. PubMed ID: 526911 [TBL] [Abstract][Full Text] [Related]
59. Chemotherapy resistance of glioblastoma stem cells. Eramo A; Ricci-Vitiani L; Zeuner A; Pallini R; Lotti F; Sette G; Pilozzi E; Larocca LM; Peschle C; De Maria R Cell Death Differ; 2006 Jul; 13(7):1238-41. PubMed ID: 16456578 [No Abstract] [Full Text] [Related]
60. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Goldie JH; Coldman AJ Cancer Res; 1984 Sep; 44(9):3643-53. PubMed ID: 6744284 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]